FDA: Drugmakers should be hands-on in contractor ops

Expect FDA inspectors to ask drugmakers how they monitor their contract manufacturers. That's according to the FDA's Rick Friedman, paraphrased in the QA Pharm blog.

Recent warning letters have made clear the relationship that the FDA expects between drugmakers and their contractors. Drug companies need to do their up-front work--due diligence audits, quality agreements and supply agreements--but the FDA expects evidence of additional involvement via certain tasks that must not be delegated, says the anonymous columnist.

The FDA inspector must be reassured--reports of GMP audits of contractor facilities must be submitted, for example. Companies should make sure the inspector is aware they have observed their product being manufactured and been hands-on enough to have made the accept/reject decision on final batches of product. The regulator also wants to know drugmakers are monitoring the contractor by tracking product quality data and quality system performance, by approving changes that may affect validated processes, and by approving batch rework and reprocessing.

- read the blog

Suggested Articles

Cadila Healthcare is looking for outside manufacturing partners to add 70 million doses of its experimental COVID-19 vaccine to its arsenal.

The COVID-19 pandemic has disrupted another biopharma company's plan to launch a new medicine.

Two prominent pneumococcal vaccines from Merck and Pfizer are running low in Europe in a possible ill omen for the coming winter: report.